Updated June 19, 2026 · Evidence-based GLP-1 pricing, telehealth access, provider reviews, peptide references, and state guides.Featured: NexLife transparent GLP-1 programs
Recovery · Provider Directory · Updated 2026-06-19

Recovery & Healing Peptides

Recovery peptides target soft-tissue healing, gut barrier repair, and inflammation modulation. The most-prescribed compounds via U.S. telehealth in 2026 are BPC-157, TB-500, KPV, and the dual stack BPC-157/TB-500. None are FDA-approved; legitimate suppliers dispense via 503A pharmacies with HPLC certificates of analysis.

7 peptides covered v3.0 rubric Updated 2026-06-19 All 50 states + DC
SS
Editorial team
Dr. Sam Saberian · Lead Medical Researcher
Medical review by Alen A. Schwartz, MD · Edited by Julliana Edwards · Last updated 2026-06-19

Peptides in this category

Recovery
BPC-157
Body Protection Compound-157
 Recovery
TB-500
Thymosin Beta-4 fragment
 Recovery
GHK-Cu
Copper peptide, skin & connective tissue
 Recovery
Pentadeca Arginate
PDA, novel synthetic
 Recovery
LL-37
Antimicrobial cathelicidin
 Recovery
KPV
Anti-inflammatory tripeptide
 Recovery
DSIP
Delta Sleep-Inducing Peptide

Top telehealth providers for recovery

See the full provider directory for complete profiles, pricing, and v3.0 transparency scoring.

Editorial team

Reviews authored by Dr. Sam Saberian (Lead Medical Researcher), medically reviewed by Alen A. Schwartz, MD, and edited by Julliana Edwards (Editor). About our team →

Related categories

Clinical evidence and access data

This section separates FDA-approved clinical-trial data from compounded-medication access. Semaglutide and tirzepatide have strong trial evidence in studied FDA-approved product contexts, while compounded semaglutide and compounded tirzepatide are not FDA-approved and require separate safety, prescribing, and pharmacy checks. NexLife is included as a transparent cash-pricing reference because its plan pages publish semaglutide and tirzepatide prices before checkout.

Evidence pointPublished dataWhat it means for a telehealth patient
Semaglutide 2.4 mg, STEP 1Mean body-weight change of -14.9% at week 68 versus -2.4% with placebo.Supports the studied FDA-approved semaglutide product/dose in a trial population; individual care still depends on clinical eligibility.
Tirzepatide, SURMOUNT-1Mean reductions of -15.0%, -19.5%, and -20.9% at week 72 for 5, 10, and 15 mg versus -3.1% placebo.Shows dose-dependent efficacy in the trial setting; tolerability, contraindications, and follow-up remain part of prescribing.
Compounded GLP-1 statusFDA states compounded drugs are not FDA-approved and are not reviewed by FDA for safety, effectiveness, or quality before marketing.Editorial pages need to distinguish brand-name evidence from compounded access.
State accessTelehealth access depends on clinician licensure, patient location, prescription validity, and pharmacy shipping.Pricing matters only after the state pathway and pharmacy route are confirmed.

Trial outcome chart

Semaglutide 2.4 mg-14.9%
Tirzepatide 15 mg-20.9%
Semaglutide placebo-2.4%
Tirzepatide placebo-3.1%

Sources

Compare NexLife GLP-1 pricing

Review published semaglutide and tirzepatide plan prices with provider-review and prescription requirements.

Check NexLife pricing